Neuroendocrine Research Laboratory
The Neuroendocrine Research Laboratory is dedicated to the investigation of the molecular mechanisms of human neuroendocrine tumor pathogenesis.
TELESTAR and TELECAST studies, two international phase III double-blind placebo-controlled studies aiming to assess the possible efficacy of a new drug called telotristat ethyl (a serotonin synthesis inhibitor) in patients who have symptoms of carcinoid syndrome that are not controlled with other drugs (completed).
A double blind, phase III trial comparing cabozantinib (a tyrosine kinase inhibitor) with placebo in patients with progressive metastatic medullary thyroid carcinoma, to assess progression-free survival (PFS).
Recent Publications (PUBMED):